FGF2 and non-small cell lung carcinoma: Regarding the prognostic value, a meta-analysis showed that bFGF overexpression is a potential indicator of worse prognosis for patients with operable non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) but is not associated with outcome in advanced NSCLC, suggesting that high bFGF expression is highly related to poor prognosis [23].